BIO-PATH HOLDINGS

Bio-Path Holdings is actively developing new targets for hematopoietic diseases and solid tumors and collaborates with academic and clinical leaders to build programs in and beyond oncology... Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers. The company's lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in previously untreated AML patients who are not eligible for or who have decided to forego intensive chemotherapy because of their fragile health. The Company's second product BP1002 (Liposomal Bcl-2 Antisense) is being evaluated in Phase 1 trials in patients with refractory/relapsed lymphoma and AML... Bio-Path is located in the heart of Houston, on the edge of the Texas Medical Center campus, which is home to leaders in research, medicine, and..

Also known as: Bio-Path, Bio-Path Holdings, Inc.

Primary location: Bellaire United States